Empagliflozin after Acute Myocardial Infarction
Source: View publication →
In patients with acute myocardial infarction at high risk for heart failure, empagliflozin did not significantly lower the risk of a first hospitalization for heart failure or death from any cause, although it did reduce the risk of incident and recurrent heart failure hospitalizations.
Key Findings
Study Design
Study Limitations
Clinical Significance
EMPACT-MI demonstrated that routine initiation of empagliflozin within 14 days of an acute myocardial infarction does not significantly reduce the overall composite risk of all-cause mortality or first heart failure hospitalization. Despite missing its primary endpoint, the therapy safely and significantly reduced the specific risk of incident and recurrent heart failure hospitalizations without an excess of adverse events. These findings suggest that while SGLT2 inhibitors may not confer a short-term mortality benefit in stable post-MI patients receiving robust background therapy, they remain highly effective tools for preventing de novo heart failure and managing congestion in this vulnerable population.
Historical Context
SGLT2 inhibitors, including empagliflozin, have revolutionized the management of chronic heart failure across the ejection fraction spectrum, chronic kidney disease, and type 2 diabetes by robustly reducing heart failure hospitalizations and cardiovascular mortality. Given that patients recovering from an acute myocardial infarction are at high risk of developing incident heart failure, investigators hypothesized that early SGLT2 inhibition could mitigate post-MI ventricular remodeling, reduce congestion, and improve survival. Alongside the contemporary DAPA-MI trial, EMPACT-MI tested this hypothesis but faced the challenge of demonstrating incremental mortality benefits in an era of rapid reperfusion and aggressive guideline-directed medical therapies, where baseline event rates have substantially declined. While the trial was formally neutral on its composite primary endpoint, it reinforced the unique and consistent efficacy of SGLT2 inhibitors in reducing heart failure events across the cardiovascular continuum.
Guided Discussion
High-yield insights from every perspective
SGLT2 inhibitors like empagliflozin were originally developed for diabetes but are now cornerstone heart failure therapies. What are the proposed mechanisms by which empagliflozin benefits the failing heart, and why might these mechanisms theoretically be beneficial in the immediate post-MI period?
Key Response
SGLT2 inhibitors promote osmotic diuresis and natriuresis (reducing preload), decrease arterial stiffness (reducing afterload), shift myocardial metabolism from glucose to ketone bodies (improving energetics), and inhibit the Na+/H+ exchanger. Post-MI, these effects theoretically reduce myocardial oxygen demand and adverse remodeling, providing the pathophysiological rationale for trials like EMPACT-MI.
Given the EMPACT-MI results showing no significant reduction in the primary composite of first HF hospitalization or all-cause mortality, how does this affect your decision to initiate an SGLT2 inhibitor in a patient presenting with an acute MI who does not have a prior history of heart failure or diabetes?
Key Response
The trial suggests routine initiation of SGLT2 inhibitors purely for post-MI cardioprotection in patients without other indications (like DM, established HF, or CKD) is not supported by the primary outcome. Residents must recognize that while safe, the lack of primary endpoint benefit means SGLT2i initiation should be driven by established indications rather than acute MI alone.
EMPACT-MI demonstrated a reduction in total (first and recurrent) heart failure hospitalizations despite missing its primary composite endpoint. How should cardiologists interpret this discordance between the neutral primary endpoint and the positive secondary signals, especially when comparing these results to the DAPA-MI trial?
Key Response
Fellows must grapple with competing risks and trial statistics. The primary endpoint was driven heavily by mortality, which was unaffected by the drug, diluting the HF hospitalization benefit. This aligns with DAPA-MI, where dapagliflozin also failed to reduce hard clinical endpoints post-MI. It suggests SGLT2is prevent congestion post-MI but do not alter the acute ischemic mortality trajectory.
As an attending guiding a clinical team, how do you synthesize the EMPACT-MI and DAPA-MI data to teach the concept of indication creep versus precision medicine in cardiovascular pharmacotherapy?
Key Response
Attendings must teach evidence-based restraint. While SGLT2 inhibitors are highly effective in chronic HF and CKD, EMPACT-MI teaches us that early post-MI pathophysiology (scar expansion, arrhythmias, acute rupture) is fundamentally different from chronic remodeling or congestion. It highlights the importance of matching the right drug to the right pathophysiological state.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The EMPACT-MI trial used a time-to-first-event analysis for its primary endpoint but analyzed total events (first and recurrent) as secondary endpoints. What are the statistical implications and potential biases of relying on recurrent event analyses when the primary time-to-first-event analysis is neutral?
Key Response
Recurrent event analyses increase statistical power by capturing the full burden of disease, but they can be heavily influenced by a small subset of patients with multiple events. If mortality (a terminal event) is unchanged or slightly worse, recurrent event models can yield biased estimates of benefit if the competing risk of death is not rigorously accounted for using joint frailty models.
If you were reviewing the EMPACT-MI manuscript, how would you critique the authors framing of the positive secondary endpoint (reduced incident and recurrent HF hospitalizations) in the context of a neutral primary composite endpoint, and what guidelines would you enforce regarding spin?
Key Response
Editors must guard against spin. According to CONSORT guidelines, when a primary endpoint is neutral, secondary endpoints should be considered hypothesis-generating and interpreted with caution, especially without correction for multiplicity. A strict reviewer would demand that the abstract and conclusion emphasize the neutral primary outcome to prevent unwarranted clinical adoption based on exploratory signals.
Current ACC/AHA guidelines strongly recommend SGLT2 inhibitors for established HFrEF (Class 1) and HFpEF (Class 2a). Based on the EMPACT-MI findings, should the guidelines be updated to recommend routine SGLT2 inhibitor initiation in the acute MI setting for the prevention of incident heart failure?
Key Response
Guideline committees require robust, positive primary endpoint data from adequately powered RCTs to change recommendations. Because EMPACT-MI and DAPA-MI failed to meet their primary endpoints for reducing HF hospitalization or death post-MI, there is insufficient evidence to grant a new recommendation for acute MI without concurrent established HF, CKD, or DM. Routine post-MI guidelines should remain unchanged regarding SGLT2 inhibitors.
Clinical Landscape
Noteworthy Related Trials
EMPA-REG OUTCOME Trial
Tested
Empagliflozin 10mg or 25mg daily
Population
Patients with Type 2 diabetes and established cardiovascular disease
Comparator
Placebo
Endpoint
3-point MACE (CV death, nonfatal MI, nonfatal stroke)
EMPEROR-Reduced Trial
Tested
Empagliflozin 10mg daily
Population
Patients with heart failure and reduced ejection fraction (HFrEF) with or without T2DM
Comparator
Placebo
Endpoint
Composite of cardiovascular death or hospitalization for heart failure
DAPA-MI Trial
Tested
Dapagliflozin 10mg daily
Population
Patients with acute MI and impaired LV function, without prior diabetes or chronic HF
Comparator
Placebo
Endpoint
Hierarchical composite of cardiometabolic outcomes (win ratio)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis